News

The University of Kentucky is participating in a nationwide study that seeks to understand why some people have prolonged symptoms (long COVID) or develop new or returning symptoms after an acute bout of SARS-CoV-2 infection.

The “Healthy Together Through Vaccinations” grant from the Kentucky Association of Health Plans (KAHP) aims to increase vaccine acceptance in the state.

Dr. Dutch returns to the ‘Behind the Blue’ podcast to discuss a wide range of pandemic topics including the Omicron variant, what it means for testing and vaccines, and best practices for the University community.

For this “UK at the Half,” Lisa Cassis, vice president for research at the University of Kentucky, shares how leaders across campus came together to find a path forward for research during the COVID-19 pandemic.

UK researchers studied pandemic-related impacts to food systems including changes in consumer purchasing behaviors, pandemic responses of different food system sectors, innovations and agency support.

The University of Kentucky is a site for KidCOVE, a national trial by Moderna to test the safety and effectiveness of its COVID-19 vaccine in children. The vaccine may protect young children 6 months to those under 12 years of age if they come into contact with the SARS-CoV-2 virus. 

Researchers found that most Americans were willing to take a COVID-19 test and valued having options when it came to how, when and where they were tested.

In January 2021, the Center for Muscle Biology (CMB) officially transferred from the UK College of Medicine to become a part of the UK College of Health Sciences.

Immunocompromised individuals who have previously received two doses of either the Pfizer or the Moderna COVID-19 vaccines are eligible to request a third dose.

The University of Kentucky has been selected as a site for a trial to assess dose levels of a Johnson & Johnson booster shot.